Takeda Inks Licensing Option Agreement with Gene Editing Platform Developer Emendo
Wednesday, April 24, 2019 12:00 AM

Takeda Pharmaceutical has advanced further into gene editing, inking a licensing option agreement with and, through its venture capital arm, investing in Emendo Biotherapeutics, the gene editing discovery platform developer said today.

The value of the agreement and the investment were not disclosed.

Through the licensing option agreement, Emendo has granted Takeda the option to use its proprietary nuclease program OMNI to edit two genes as part of the pharma’s R&D efforts to treat unspecified genetic disorders.

Augusta University Medical Center moving forward on $150M hospital, medical campus
Monday, April 22, 2019 12:00 AM

Augusta University Medical Center is moving forward with plans to construct a new hospital and medical campus on Interstate 20 in Columbia County, Ga., 13 miles west of downtown Augusta.

AU Medical Center on April 19 filed plans with the state of Georgia for the project as a development of regional impact. Plans call for a medical mixed-use campus consisting of an approximately 600,000-square-foot hospital with associated uses, approximately 125,000 square feet of medical office buildings, and approximately 60,000 square feet of professional, health, and retail uses.

Earlier in April, AU Medical Center filed to rezone the 52-acre site of the proposed medical campus. Check out a site plan here. The project is being designed by Catalyst Design Group of Nashville, Tenn.

Recro, Teva Extend License and Supply Agreement
Wednesday, April 17, 2019 12:00 AM

CDMO Recro Gainesville will continue to supply Verapamil SR capsules through 2024

Recro Gainesville, the contract development and manufacturing organization (CDMO) division of Recro Pharma, has amended its existing license and supply agreement with Teva Pharmaceutical to extend the agreement for six years, effective January 1, 2019.
Under the terms of the amended agreement, Recro Gainesville will continue to supply Teva with Verapamil SR capsules through 2024 and Teva will continue to be Recro Gainesville’s exclusive U.S. distributor of the product, for which Recro Gainesville is the New Drug Application (NDA) holder. The 2019 Teva agreement provides to Recro Gainesville the same revenue economics as the original agreement, including both manufacturing and profit sharing components. Prior to this amendment, the license and supply agreement with Teva for Verapamil SR was renewable on a year-to-year basis. 

Georgia Bio CEO: Investment in life sciences has produced 14.9% growth in jobs
Wednesday, April 17, 2019 12:00 AM

Georgia’s life science industry has experienced a 14.9 percent growth in employment during the past decade, according to the results of the 2019 Georgia Life Sciences State of the Industry Report released Wednesday morning.

That was nearly double the growth of life sciences employment nationally – 7.7 percent – over the same decade (2007 to 2017).

“We can attribute this growth to increased investment in research and our academic institutions,” said Maria Thacker-Goethe, president and CEO of Georgia Bio.

Boehringer Ingelheim, PureTech to Partner on Cancer Immunotherapies
Wednesday, April 17, 2019 12:00 AM

Boehringer Ingelheim plans to develop new immuno-oncology treatments for an undisclosed number of targets using PureTech Health’s lymphatic targeting technology for immune modulation, through a collaboration that PureTech said today could generate for it more than $226 million.

The companies will initially focus on applying PureTech’s internally-developed lymphatic targeting platform to an unspecified Boehringer Ingelheim immuno-oncology candidate for gastrointestinal (GI) cancers that is administered directly to the gut lymphatics, PureTech said.

PureTech specializes in developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis. The company’s platform is designed to harness the gut’s lipid transport mechanisms to enable oral administration and transport of drug candidates directly through the gut-draining lymphatic vasculature, also bypassing first pass metabolism in the liver.

<< first < Prev 1 2 3 4 5 6 7 8 9 10 Next > last >>

Page 3 of 46